X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3984) 3984
Newsletter (106) 106
Newspaper Article (40) 40
Book Chapter (19) 19
Dissertation (11) 11
Magazine Article (9) 9
Conference Proceeding (8) 8
Publication (2) 2
Transcript (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
dasatinib (3632) 3632
humans (2664) 2664
oncology (1491) 1491
imatinib (1226) 1226
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (1078) 1078
hematology (1072) 1072
female (994) 994
chronic myeloid leukemia (966) 966
male (964) 964
nilotinib (892) 892
imatinib mesylate (875) 875
protein kinase inhibitors - therapeutic use (870) 870
pyrimidines - therapeutic use (852) 852
chronic myelogenous leukemia (764) 764
middle aged (763) 763
cancer (751) 751
chronic myeloid-leukemia (728) 728
antineoplastic agents - therapeutic use (718) 718
adult (670) 670
protein kinase inhibitors - pharmacology (646) 646
animals (634) 634
thiazoles - therapeutic use (632) 632
leukemia (631) 631
pyrimidines - pharmacology (609) 609
aged (608) 608
research (561) 561
benzamides (538) 538
tyrosine (537) 537
cell line, tumor (497) 497
treatment outcome (490) 490
hemic and lymphatic diseases (481) 481
thiazoles - pharmacology (467) 467
tyrosine kinase inhibitors (451) 451
therapy (447) 447
care and treatment (433) 433
piperazines - therapeutic use (433) 433
bcr-abl (429) 429
mutation (420) 420
protein-tyrosine kinases - antagonists & inhibitors (418) 418
mice (417) 417
tyrosine kinase inhibitor (414) 414
antineoplastic agents - pharmacology (389) 389
pyrimidines - adverse effects (365) 365
resistance (348) 348
kinases (346) 346
pharmacology & pharmacy (343) 343
leukemia, myelogenous, chronic, bcr-abl positive - genetics (342) 342
drug therapy (340) 340
protein kinase inhibitors - adverse effects (340) 340
pyrimidines - administration & dosage (334) 334
drug resistance, neoplasm (332) 332
cml (330) 330
fusion proteins, bcr-abl - genetics (329) 329
analysis (325) 325
follow-up (306) 306
aged, 80 and over (291) 291
protein kinase inhibitors - administration & dosage (287) 287
activation (283) 283
tyrosine kinase (280) 280
chemotherapy (278) 278
chronic-phase (272) 272
antineoplastic agents - adverse effects (265) 265
dasatinib - therapeutic use (265) 265
leukemia, myelogenous, chronic, bcr-abl positive - pathology (258) 258
apoptosis (256) 256
expression (253) 253
young adult (253) 253
phosphorylation (252) 252
thiazoles - adverse effects (249) 249
dasatinib - pharmacology (248) 248
thiazoles - administration & dosage (245) 245
health aspects (244) 244
src-family kinases - antagonists & inhibitors (242) 242
antineoplastic agents (235) 235
protein-tyrosine kinase (234) 234
src (233) 233
src-family kinases - metabolism (230) 230
fusion proteins, bcr-abl - antagonists & inhibitors (228) 228
hematology, oncology and palliative medicine (226) 226
cell proliferation - drug effects (222) 222
cytogenetic responses (221) 221
medicine & public health (221) 221
in-vitro (220) 220
genetic aspects (217) 217
apoptosis - drug effects (215) 215
dosage and administration (212) 212
abridged index medicus (209) 209
cell biology (209) 209
antimitotic agents (208) 208
philadelphia chromosome (208) 208
imatinib-resistant (206) 206
prognosis (205) 205
patients (204) 204
piperazines - pharmacology (204) 204
antineoplastic agents - administration & dosage (203) 203
survival (203) 203
adolescent (202) 202
antineoplastic combined chemotherapy protocols - therapeutic use (199) 199
kinase inhibitor (199) 199
cells (196) 196
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3981) 3981
Japanese (60) 60
Chinese (36) 36
French (29) 29
Polish (24) 24
Russian (24) 24
German (17) 17
Spanish (17) 17
Czech (10) 10
Korean (8) 8
Portuguese (7) 7
Turkish (6) 6
Danish (2) 2
Hebrew (2) 2
Italian (2) 2
Slovenian (2) 2
Finnish (1) 1
Hungarian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5915 - 5915
Abstract Introduction Survival outcomes for patients with lymphoid, myeloid and plasma cell malignancies, have improved with the use of oral small molecule... 
Journal Article
Biosensors & bioelectronics, ISSN 0956-5663, 2016, Volume 86, pp. 879 - 884
Journal Article
Journal Article
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 2016, Volume 122, Issue 6, pp. 868 - 874
Journal Article
Journal of controlled release, ISSN 0168-3659, 2017, Volume 258, pp. 43 - 55
Two novel prodrug polymers POEG-b-PSSDas (redox-sensitive) and POEG-b-PCCDas (redox-insensitive), which consist of poly(oligo(ethylene glycol) methacrylate)... 
Prodrug micelles | Dasatinib | Redox responsive | Co-delivery | Doxorubicin | DESIGN | DRUG-DELIVERY | OVARIAN-CANCER | ANTITUMOR-ACTIVITY | CHEMISTRY, MULTIDISCIPLINARY | CHRONIC MYELOID-LEUKEMIA | PACLITAXEL | BREAST-CANCER CELLS | FAMILY KINASE INHIBITOR | IMATINIB | PHARMACOLOGY & PHARMACY | MULTIDRUG-RESISTANCE | Prodrugs - administration & dosage | Doxorubicin - therapeutic use | Humans | Dasatinib - pharmacokinetics | Delayed-Action Preparations - chemistry | Polyethylene Glycols - chemistry | Drug Delivery Systems | Micelles | Female | Antibiotics, Antineoplastic - pharmacokinetics | Doxorubicin - administration & dosage | Protein Kinase Inhibitors - pharmacokinetics | Cell Survival - drug effects | Oxidation-Reduction | Dasatinib - therapeutic use | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Animals | Dasatinib - administration & dosage | Antibiotics, Antineoplastic - therapeutic use | Prodrugs - pharmacokinetics | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Mice, Inbred BALB C | Prodrugs - therapeutic use | Neoplasms - pathology | Ethylene glycol | Anthracyclines | Chemotherapy | Polymers | Analysis | Cancer | Tyrosine | Medical colleges | Pharmacogenetics | Pharmacy | Physiological aspects | Drugstores | co-delivery | dasatinib | doxorubicin | prodrug micelles | redox responsive
Journal Article
European journal of clinical pharmacology, ISSN 1432-1041, 2015, Volume 72, Issue 2, pp. 185 - 193
Dasatinib is a novel, oral, multi-targeted kinase inhibitor of breakpoint cluster region-abelson (BCR-ABL) and Src family kinases. The study investigated... 
Dasatinib | Pharmacodynamics | Biomedicine | Half maximal inhibitory concentration | Phamacokinetics | Pharmacology/Toxicology | Molecular response | CELLS | SAFETY | TYROSINE KINASE | NILOTINIB | PHILADELPHIA-CHROMOSOME | IMATINIB | DRUGS | BCR-ABL ACTIVITY | PHARMACOLOGY & PHARMACY | INHIBITOR | Leukocytes, Mononuclear - metabolism | Antigens, CD34 - metabolism | Oncogene Protein v-crk - antagonists & inhibitors | Humans | Middle Aged | Oncogene Protein v-crk - metabolism | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Dasatinib - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Phosphorylation - drug effects | Protein Kinase Inhibitors - pharmacokinetics | Leukocytes, Mononuclear - drug effects | Dasatinib - therapeutic use | Treatment Outcome | Dasatinib - pharmacology | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Aged | Dasatinib - adverse effects | Protein Kinase Inhibitors - pharmacology | Phosphotransferases | Analysis | Chronic myeloid leukemia | Pharmacology | Kinetics | Drug therapy | Leukemia | Chronic illnesses
Journal Article
The Journal of clinical investigation, ISSN 1558-8238, 2016, Volume 126, Issue 9, pp. 3207 - 3218
Pulmonary arterial hypertension (PAH) is a life-threatening disease that can be induced by dasatinib, a dual Src and BCR-ABL tyrosine kinase inhibitor that is... 
MEDICINE, RESEARCH & EXPERIMENTAL | FIBROBLAST GROWTH FACTOR-2 | CELLS | ENDOTHELIAL DYSFUNCTION | THERAPEUTIC STRATEGY | INDUCED APOPTOSIS | TYROSINE KINASE | ARTERIAL-HYPERTENSION | BCR-ABL | ENDOPLASMIC-RETICULUM STRESS | CHRONIC MYELOID-LEUKEMIA | Reactive Oxygen Species - metabolism | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | E-Selectin - blood | Male | Hypertension, Pulmonary - chemically induced | Hypoxia - metabolism | Antineoplastic Agents - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Adult | Female | Intercellular Adhesion Molecule-1 - blood | Antineoplastic Agents - pharmacology | Genetic Predisposition to Disease | Imatinib Mesylate - pharmacology | Cells, Cultured | Rats | Mitochondria - metabolism | Vascular Cell Adhesion Molecule-1 - blood | Dasatinib - pharmacology | Animals | Lung - drug effects | Dasatinib - adverse effects | Hemodynamics | Lung - blood supply | Apoptosis | Dasatinib | Research | Health aspects | Pulmonary hypertension | Risk factors | Scholarships & fellowships | Toxicity | Mortality | Rodents | Leukemia | Hypoxia | Grants | Laboratory animals | Experiments | Drug dosages | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology | Cellular Biology | Cardiology and cardiovascular system | Pulmonology and respiratory tract
Journal Article
Annals of hematology, ISSN 1432-0584, 2017, Volume 97, Issue 1, pp. 95 - 100
Journal Article
Applied Biochemistry and Biotechnology, ISSN 0273-2289, 7/2018, Volume 185, Issue 3, pp. 655 - 675
UM-164, a potent Src/p38 inhibitor, is a promising lead compound for developing the first targeted therapeutic strategy against triple-negative breast cancer... 
Biochemistry, general | Biotechnology | Chemistry | UM-164 | Src | Molecular dynamics | TNBC | Dual kinase inhibitor and DFG-out | MOLECULAR-DYNAMICS | DOCKING | BIOCHEMISTRY & MOLECULAR BIOLOGY | DASATINIB | SOFTWARE | AMBER | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | GROWTH | INHIBITOR | Catalytic Domain | Humans | Molecular Conformation | Dasatinib - therapeutic use | Antineoplastic Agents - therapeutic use | Proto-Oncogene Proteins pp60(c-src) - antagonists & inhibitors | Dasatinib - chemistry | Antineoplastic Agents - chemistry | Triple Negative Breast Neoplasms - drug therapy | Dasatinib - metabolism | Molecular Dynamics Simulation | Proto-Oncogene Proteins pp60(c-src) - chemistry | Thermodynamics | Hydrogen Bonding | Dasatinib - analogs & derivatives | Proto-Oncogene Proteins pp60(c-src) - metabolism | Hydrophobic and Hydrophilic Interactions | Protein Binding | Female | Ligands | Principal Component Analysis | Care and treatment | Hydrogen | Analysis | Breast cancer | Hydrogen bonding | Protein binding | Binding | Depth perception | Computer simulation | Principal components analysis | Hydrophobicity | c-Src protein | Src protein | Chemical compounds | Free energy | Rings (mathematics) | Proteins | Inhibitors | Hydrogen bonds | Correlation analysis | Computer applications | Chemical bonds | Lead | Fluorination | Binding sites | Cancer
Journal Article
Cancer, ISSN 0008-543X, 2015, Volume 121, Issue 23, pp. 4158 - 4164
BACKGROUND The long‐term efficacy of a combination of chemotherapy and dasatinib in patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic... 
dasatinib |